Asciminib
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Myeloid Leukemia in Chronic Phase
Conditions
Chronic Myeloid Leukemia in Chronic Phase
Trial Timeline
— → —
NCT ID
NCT04360005About Asciminib
Asciminib is a pre-clinical stage product being developed by Novartis for Chronic Myeloid Leukemia in Chronic Phase. The current trial status is active. This product is registered under clinical trial identifier NCT04360005. Target conditions include Chronic Myeloid Leukemia in Chronic Phase.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04360005 | Pre-clinical | Active |
| NCT07250087 | Phase 1 | Recruiting |
| NCT06629584 | Phase 2 | Recruiting |
| NCT06427811 | Approved | Active |
| NCT06236724 | Phase 2 | Recruiting |
| NCT05384587 | Phase 2 | Active |
| NCT04795427 | Phase 2 | Completed |
| NCT03605277 | Phase 1 | Completed |
Competing Products
20 competing products in Chronic Myeloid Leukemia in Chronic Phase
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |